Iradimed Corp. (IRMD) Tops Q1 EPS by 1c; offers guidance

Iradimed Corp. (NASDAQ: IRMD) reported Q1 EPS of $0.42, $0.01 better than the analyst estimate of $0.41. Revenue for the quarter came in at $19.5 million versus the consensus estimate of $19.13 million.

GUIDANCE:

Iradimed Corp. sees Q2 2025 EPS of $0.41-$0.44, versus the consensus of $0.43. Iradimed Corp. sees Q2 2025 revenue of $19.7-19.9 million, versus the consensus of $19.806 million.

Iradimed Corp. sees FY2025 EPS of $1.71-$1.81, versus the consensus of $1.75. Iradimed Corp. sees FY2025 revenue of $78-82 million, versus the consensus of $79.405 million.

For earnings history and earnings-related data on Iradimed Corp. (IRMD) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• Zeta Surgical begins TMS navigation treatments at Hope Therapeutics clinics
• Morgan Stanley upgrades CDW on stronger AI-driven server demand